摘要
乙型肝炎病毒(HBV)仍然是全世界面临的对人类危害最大的病原体之一。核苷(酸)类似物药物可以有效抑制HBV的复制,目前已成为治疗HBV感染的首选药物。患者长期用药会导致对耐核苷(酸)类似物的HBV突变体的选择,影响药物的继续使用。本文参考近年来国内外有关研究进展,对核苷(酸)类似物的作用机制和HBV对其的耐药机制作一综述。
Hepatitis B virus remains one of the most harmful pathogens to mankind world wide. Nucleos（t）ide analogs are able to inhibit the replication of HBV efficiently. They have become the primary choice in the treatment of chronic HBV infection. Nevertheless, long-term therapy of nucleos（t）ide analogs leads to the selection of drug-resistant mutants. Based on the recent findings in anti-HBV therapy, this review aims to summarize the inhibitory mechanisms of nucleos（t）ide analogs in HBV replication and the drug resistance on nucleos（t）ide analogs treatment of hepatitis B.
出处
《中国抗生素杂志》
CAS
CSCD
北大核心
2009年第4期193-199,共7页
Chinese Journal of Antibiotics
基金
国家自然科学基金(No.30070905)
陕西省重点实验室基金资助(No:03JS008
04JS06)
关键词
HBV
核苷类似物
抑制机制
耐药机制
HBV
Nucleos（t）ide analogs
Inhibitory mechanism
Drug resistance
